Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2021-04-08 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司首次公开发行限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares following the company's initial public offering (IPO). It details the number of shares becoming tradable, lock-up periods, shareholder commitments, and regulatory approvals. The text includes specific dates, share quantities, shareholder names, and compliance statements from the sponsor institution. It does not contain financial statements, earnings data, or management discussion but focuses on share circulation and regulatory compliance related to share restrictions lifting. This type of document is a regulatory announcement about share capital changes and shareholder commitments rather than a financial report or earnings release. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief report publication announcement or a simple regulatory filing but a detailed capital change announcement.
2021-04-08 Chinese
中国国际金融股份有限公司关于成都先导药物开发股份有限公司首次公开发行限售股上市流通的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (China International Capital Corporation) regarding the listing and circulation of restricted shares following the initial public offering (IPO) of Chengdu Lead Pharma Co., Ltd. It references regulatory approvals, lock-up periods, shareholder commitments, and compliance with securities laws. The document is not a financial report like an annual or interim report, nor is it a simple announcement. It is a formal audit or verification opinion related to the IPO and share circulation compliance, which fits the category of an Audit Report / Information (AR). The document length (6125 characters) and detailed content support this classification rather than a brief announcement or regulatory filing. Q2 2021
2021-04-08 Chinese
成都先导药物开发股份有限公司2020年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2020 Annual Performance Express Announcement" and contains preliminary financial data for the year 2020, including revenue, profit, net income, and other key financial metrics. It explicitly states that the data is preliminary and unaudited, and the final audited data will be in the company's 2020 Annual Report. The document is relatively short (2157 characters) and serves as a quick financial performance update rather than a full annual report. This type of document is typically classified as an Earnings Release (ER) because it provides initial key financial results highlights for the fiscal year but is not the full audited annual report (10-K). FY 2020
2021-02-26 Chinese
关于成都先导药物开发股份有限公司股票交易异常波动问询函的回函
Regulatory Filings Classification · 95% confidence The document is a response letter from the controlling shareholder and actual controller of the company regarding an inquiry about abnormal stock trading fluctuations. It explicitly states that there are no undisclosed major matters affecting stock trading and no share transactions during the period. The document is short (436 characters) and is a reply to a regulatory inquiry, not a financial report or announcement of financial results. It does not contain financial data, management changes, or voting results. It fits best as a Regulatory Filing (RNS) because it is a compliance-related response to a regulatory inquiry about stock trading activity.
2021-02-02 Chinese
成都先导药物开发股份有限公司股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement by the board of Chengdu Lead Drug Development Co., Ltd. regarding abnormal stock price fluctuations over two trading days. It references stock price changes, regulatory rules from the Shanghai Stock Exchange, and confirms no undisclosed material information or insider trading. The document serves to inform investors about the stock price volatility and associated risks, without containing financial statements or detailed financial data. It is a regulatory disclosure about stock trading activity rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2021-02-02 Chinese
2020年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is titled as a '2020 Annual Performance Forecast Announcement' from Chengdu Lead Drug Development Co., Ltd. It provides preliminary financial performance estimates for the full year 2020, including expected revenue and net profit decreases compared to the previous year. It explicitly states that the forecast is unaudited and preliminary, and that the final audited financial data will be disclosed in the formal annual report. The document is short (1368 characters) and serves as an earnings guidance or forecast rather than a full financial report. It does not contain actual audited financial statements or comprehensive financial analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results or forecasts with key highlights only. FY 2020
2021-01-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.